MicroRNAs modulated by DPP-4 inhibitor and bedtime NPH insulin therapy in individuals with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at NPH Insulin (isophane).

To evaluate the effects of bedtime NPH insulin and sitagliptin on serum miRNA expression in individuals with type 2 diabetes (T2D), thirty-two patients with T2D inadequately controlled with metformin and glyburide were randomly assigned to an additional 6-month treatment with either bedtime NPH insulin or sitagliptin.

Why It Was Studied

MicroRNAs (miRNAs) and their target genes can elucidate mechanisms of drug action and serve as potential therapeutic biomarkers.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Before and after treatments, fasting as postprandial (60, 120, and 180 minutes) concentrations of glucose, C-peptide, glucagon-like peptide 1 (GLP1), and triglycerides were measured.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the NPH Insulin (isophane) group and the comparison group should start out alike.

Fasting HbA1c was also assessed.

Expression levels of selected miRNAs were analyzed using quantitative polymerase chain reaction.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, MicroRNAs, Sitagliptin Phosphate, Dipeptidyl-Peptidase IV Inhibitors, Insulin, Isophane, Hypoglycemic Agents and Blood Glucose.

Author keywords: DPP-4 inhibitor, basic clinical research, miRNAs and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized study of NPH Insulin (isophane).

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the NPH Insulin (isophane) compound page, all human trials.